LOSS OF CONSTITUTIONAL HETEROZYGOSITY IN HUMAN CANCER. Download Citation; Citation Alerts; Keywords. loss of heterozygosity tumor suppression cancer genetics. Previous Article Next Article From KNOWABLE MAGAZINE Unraveling breast cancer risk Annual Review of Cell and Developmental Biology Immune Therapy for Cancer Michael Dougan andLoss of Constitutional Heterozygosity in Human Cancer 295 nonrandom LOH was additionally found on 13 and 17. 95For 17, the pattern of LOH was interpreted as mainly due to mitotic recombination, resulting in retention of heterozygosity at some loci, and at other loss loss of constitutional heterozygosity in human cancer
Krontiris TG, DiMartino NA, Colb M, Parkinson DR. Unique allelic restriction fragments of the human Haras locus in leukocyte and tumour DNAs of cancer patients. Nature. 313 (6001): . Lasko D, Cavenee W, Nordenskjld M. Loss of constitutional heterozygosity in human cancer. Annu Rev Genet. 1991; 25: .
This chapter discusses a practical approach for the loss of constitutional heterozygosity in human cancer. First observed in rare heritable cancer syndromes and eliminating genes How can the answer be improved?loss of constitutional heterozygosity in human cancer Summary. Inactivation of tumour suppressor genes or antioncogenes as well as activation of dominant acting oncogenes seem to be important mechanisms in the pathogenesis of gliomas. Loss of heterozygosity (LOH) pointing to chromosomal loss or deletions was detected for at least one chromosme 17 marker in 11 gliomas
Institutional Login Login. Register Activate loss of constitutional heterozygosity in human cancer